abstract |
Methods and kits used for determining predisposition and/or diagnosis of schizophrenia, using genotypes in the DGCR2 locus are disclosed. Also disclosed are methods and drugs for treating schizophrenia. Further disclosed are methods and kits useful for prediction of drug responsiveness towards mental disorders drugs, and more specifically towards schizophrenia drugs. |